Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
WST 
West Pharmaceutical Services Inc (WST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: WST (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $345.71
1 Year Target Price $345.71
| 10 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.99% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.80B USD | Price to earnings Ratio 40.84 | 1Y Target Price 345.71 |
Price to earnings Ratio 40.84 | 1Y Target Price 345.71 | ||
Volume (30-day avg) 13 | Beta 1.17 | 52 Weeks Range 186.94 - 347.77 | Updated Date 01/9/2026 |
52 Weeks Range 186.94 - 347.77 | Updated Date 01/9/2026 | ||
Dividends yield (FY) 0.30% | Basic EPS (TTM) 6.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.29% | Operating Margin (TTM) 21.85% |
Management Effectiveness
Return on Assets (TTM) 10.22% | Return on Equity (TTM) 16.95% |
Valuation
Trailing PE 40.84 | Forward PE 37.17 | Enterprise Value 19701023637 | Price to Sales(TTM) 6.56 |
Enterprise Value 19701023637 | Price to Sales(TTM) 6.56 | ||
Enterprise Value to Revenue 6.53 | Enterprise Value to EBITDA 25.61 | Shares Outstanding 71943412 | Shares Floating 71459952 |
Shares Outstanding 71943412 | Shares Floating 71459952 | ||
Percent Insiders 0.59 | Percent Institutions 97.8 |
Upturn AI SWOT
West Pharmaceutical Services Inc
Company Overview
History and Background
West Pharmaceutical Services, Inc. was founded in 1923 by Roland West. Initially, it was a small rubber products manufacturer. Over the decades, the company evolved significantly, focusing on specialized components for pharmaceutical and medical devices. Key milestones include its expansion into international markets and its commitment to innovation in containment and delivery solutions, becoming a critical supplier to the global healthcare industry.
Core Business Areas
- Drug Containment Solutions: Designs and manufactures innovative containment and delivery systems for injectable drugs and vaccines. This includes stoppers, plungers, seals, and syringe components, crucial for preserving drug integrity and ensuring safe administration.
- Drug Delivery Systems: Develops and manufactures components for drug delivery devices such as auto-injectors, pen injectors, and inhalers. These components are essential for patient-friendly and precise drug delivery.
Leadership and Structure
West Pharmaceutical Services is led by a seasoned management team. The current CEO is Christopher G. Del Vecchio. The company operates through a divisional structure focused on its core product lines and geographic regions. It emphasizes a matrix organizational approach to foster collaboration between R&D, manufacturing, and sales.
Top Products and Market Share
Key Offerings
- Product Name 1: Westaru00ae Rubber Components (Stoppers and Plungers) - These are critical for vials and syringes, providing a hermetic seal for injectable drugs. While specific market share for individual product lines is proprietary, West is a dominant player in the pharmaceutical stoppers and plungers market. Competitors include DuPont (partially through elastomer materials), Datwyler, and other specialized rubber component manufacturers.
- Product Name 2: NovaPureu00ae Elastomeric Components - A premium line of stoppers and plungers designed for biologics and sensitive drugs, offering reduced particulate matter and extractables. Similar to Westar, West holds a significant share in this high-margin segment. Competitors include Datwyler, and specialized divisions of larger chemical companies.
- Product Name 3: Daikyo Crystal Zenithu00ae (CZ) Syringe Components - This includes plunger stoppers and pistons for pre-filled syringes, offering a glass-like alternative. West is a key partner in the distribution and manufacturing of these components. Competitors in the syringe component market include companies that offer glass and other advanced polymer solutions.
Market Dynamics
Industry Overview
The pharmaceutical packaging and drug delivery device industry is driven by increasing global demand for healthcare, a growing biologics market, and the rise of complex injectable therapies. Stringent regulatory requirements, the need for product integrity, and patient convenience are key market drivers. The industry is characterized by high R&D investment, focus on quality, and long-term supplier relationships.
Positioning
West Pharmaceutical Services is a leading global manufacturer of technologically advanced containment and delivery solutions for the pharmaceutical and biotechnology industries. Its competitive advantages lie in its deep scientific expertise, proprietary materials, robust manufacturing capabilities, extensive regulatory knowledge, and strong customer relationships. The company's focus on innovation, particularly in areas like high-potency and biologics containment, positions it well for future growth.
Total Addressable Market (TAM)
The global pharmaceutical packaging market is projected to be valued in the hundreds of billions of USD. West Pharmaceutical Services is positioned to capture a significant portion of the specialized segment within this TAM, specifically for primary packaging for injectable drugs and components for drug delivery devices. The growth of biologics and personalized medicine further expands the addressable market for West's high-value solutions.
Upturn SWOT Analysis
Strengths
- Strong brand reputation and long-standing customer relationships in the pharmaceutical industry.
- Proprietary material science and manufacturing technologies.
- Global manufacturing footprint and supply chain reliability.
- Extensive regulatory expertise and compliance.
- Focus on high-growth segments like biologics and advanced drug delivery.
Weaknesses
- Reliance on a limited number of large pharmaceutical clients.
- Potential for supply chain disruptions due to global events.
- Sensitivity to raw material price fluctuations.
- Capital-intensive nature of manufacturing and R&D.
Opportunities
- Growing demand for biologics and complex injectable drugs.
- Expansion into emerging markets and developing regions.
- Development of novel drug delivery systems and smart packaging.
- Increased outsourcing of packaging and component manufacturing by pharmaceutical companies.
- Strategic acquisitions to expand product portfolio or market reach.
Threats
- Increased competition from both established players and new entrants.
- Changes in regulatory landscapes and increased compliance costs.
- Economic downturns impacting pharmaceutical R&D and manufacturing spending.
- Technological obsolescence if innovation pace slows.
- Geopolitical instability impacting global supply chains.
Competitors and Market Share
Key Competitors
- Datwyler Holding AG (DAEW.SW)
- DuPont de Nemours, Inc. (DD)
- Becton, Dickinson and Company (BDX)
- Gerresheimer AG (GXI.DE)
- Schott AG (Private)
Competitive Landscape
West Pharmaceutical Services holds a strong competitive position due to its specialization, quality, and regulatory expertise. Its advantages include proprietary technologies and strong customer partnerships. However, competitors like Datwyler and DuPont offer broad material science solutions, and Becton Dickinson offers integrated drug delivery systems. West's ability to innovate and maintain high quality standards is crucial for sustaining its market leadership.
Major Acquisitions
Summit Packaging Systems
- Year: 2017
- Acquisition Price (USD millions):
- Strategic Rationale: To expand capabilities in sterile pharmaceutical packaging, particularly for stoppers and plungers.
Lake Region Medical
- Year: 2022
- Acquisition Price (USD millions): 180
- Strategic Rationale: To enhance its drug delivery device components business and expand its presence in advanced drug delivery systems.
Growth Trajectory and Initiatives
Historical Growth: West Pharmaceutical Services has experienced consistent historical growth, driven by global healthcare demand, the expansion of the biologics market, and its strategic focus on innovation in drug containment and delivery. The company has successfully navigated market shifts and expanded its product offerings and geographic reach.
Future Projections: Analyst estimates generally project continued revenue and earnings growth for West Pharmaceutical Services, supported by favorable industry trends such as the increasing pipeline of injectable drugs, advancements in biotechnology, and ongoing demand for safe and effective drug delivery. Projections often focus on the growth of its specialized product lines.
Recent Initiatives: Recent initiatives have included investments in expanding manufacturing capacity to meet growing demand, strategic acquisitions to enhance its technological capabilities or market access, and continued R&D investment in areas like advanced materials, sterile manufacturing, and connected drug delivery solutions.
Summary
West Pharmaceutical Services Inc is a strong player in the essential pharmaceutical packaging and drug delivery market, benefiting from consistent demand in the healthcare sector, especially for biologics. Its established reputation, proprietary technologies, and global reach are significant assets. However, the company must remain vigilant against competitive pressures, supply chain vulnerabilities, and the need for continuous innovation to maintain its market leadership and capitalize on future growth opportunities.
Similar Stocks
Sources and Disclaimers
Data Sources:
- West Pharmaceutical Services Inc. Investor Relations
- Annual Reports (10-K)
- Quarterly Reports (10-Q)
- Financial News Outlets (e.g., Bloomberg, Reuters, Wall Street Journal)
- Industry Research Reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Market share data, acquisition prices, and future projections are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About West Pharmaceutical Services Inc
Exchange NYSE | Headquaters Exton, PA, United States | ||
IPO Launch date 1978-01-13 | Non-Independent Chair of the Board, President & CEO Mr. Eric M. Green | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 10600 | Website https://www.westpharma.com |
Full time employees 10600 | Website https://www.westpharma.com | ||
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.